Cynthia M. Goldberg

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also affiliated with Merck Institute for Science Education

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study”.

Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study

The Lancet Oncology(2024)10.1016/s1470-2045(24)00389-9

N/A

1.0DataRank · unranked

37 citations

Ane B. Iversen, Vivek Narayan, Benjamin L Maughan, Kathryn E. Beckermann, Stéphane Oudard +10 more

Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2592

N/A

0DataRank · unranked

28 citations

Eric Jonasch, Othon Iliopoulos, Kathryn E. Beckermann, Vivek Narayan, Benjamin L. Maughan +10 more